Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J Shields, Joseph E Grossman, Xin Huang, Meggan Tammaro, Jean-François Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla
PURPOSE: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL DESIGN: Preclinical activity was tested in patient-derived xenograft (PDX) models of PDAC. In the open-label, phase I clinical study, the dose-escalation cohort received oral palbociclib initially at 75 mg/day (range, 50‒125 mg/day; modified 3+3 design; 3/1 schedule); intravenous nab-paclitaxel was administered weekly for 3 weeks/28-day cycle at 100‒125 mg/m2 ...
November 2022: Cancer Res Commun